Aim Immunotech Stock Price, News & Analysis

AIM ImmunoTech Inc. (NYSE American: AIM) received Orphan Drug Designation from the U.S. FDA for its drug Ampligen (rintatolimod), aimed at treating pancreatic cancer. This designation grants seven years of market exclusivity upon approval. Pancreatic cancer is notably lethal, with a five-year survival rate of only 6%. Recent data from a study at Erasmus University Medical Center indicated that patients treated with Ampligen had a median survival rate 200% higher than a historical control group. However, further testing and trials are required to confirm effectiveness.

AIM ImmunoTech Inc. announced that the FDA granted Orphan Drug Designation for its drug Ampligen (rintatolimod) to treat pancreatic cancer, a disease with a low five-year survival rate of just 6%. This designation provides seven years of market exclusivity upon approval. The company also reported statistically significant survival results from a study at Erasmus University, showing a median survival rate approximately 200% higher in patients treated with Ampligen compared to a historical control group. This suggests potential for extended survival rates against the standard care for pancreatic cancer.

AIM ImmunoTech Inc. (NYSE American: AIM) reports progress in developing treatments for COVID-19, with its collaboration in a Phase 1/2a study at Roswell Park Comprehensive Cancer Center for a two-drug regimen involving Ampligen and interferon alpha-2b. The study is underway, with the first patient treated. AIM is also focusing on intranasal prophylaxis for high-risk groups and therapies for COVID-19 Long Haulers. AIM emphasizes the need for early treatments amid vaccine developments from major pharmaceutical firms. The company remains committed to advancing its research efforts.

AIM ImmunoTech (AIM) reported third-quarter financials on November 13, 2020. Cash and equivalents surged to $54.5 million from $8.8 million at year-end 2019. Research expenses fell slightly to $1.10 million, while general expenses rose to $2.09 million. Clinically, AIM revealed promising pancreatic cancer survival data, with median survival improving by 200% for patients treated with Ampligen compared to historical controls. Additionally, significant findings were reported for ME/CFS and COVID-19, with Ampligen showing potential benefits for early-stage patients.

AIM ImmunoTech announced the publication of significant data indicating that its drug Ampligen may effectively treat myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) when used early. The research, published in PLOS ONE, revealed that 51.2% of Ampligen-treated ME/CFS patients improved their exercise duration by at least 25%. The company has expanded its AMP-511 Early Access Program to include 'Long Haulers' from COVID-19, suggesting a potential benefit from early treatment. Amidst this, AIM emphasizes the need for further research to validate these findings.

AIM ImmunoTech Inc. (NYSE American: AIM) announced that CEO Thomas K. Equels will participate in a virtual panel titled “COVID-19: Progress on Treatments & Prevention” on October 29 at 10:05 A.M. ET during the 23rd Annual BioFlorida Conference. The conference will feature discussions by global experts on BioPharma, MedTech, HealthIT, and COVID-19. Attendees can access the live webcast via the conference platform. AIM ImmunoTech is dedicated to developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19.

AIM ImmunoTech has received IRB approval for an expanded access clinical trial of Ampligen to treat chronic fatigue-like symptoms in COVID-19 patients, also known as Long Haulers. The updated protocol allows for 20 out of 100 participants to include those who have been diagnosed with SARS-CoV-2 but still show symptoms. AIM anticipates a rise in Chronic Fatigue Syndrome (CFS) cases post-COVID-19 and is preparing to submit the IRB-approved protocol to the FDA. This also follows a provisional patent application for Ampligen as a therapy for COVID-19-induced ME/CFS-like illnesses.

AIM ImmunoTech announced statistically significant positive results in pancreatic cancer survival from an Early Access Program at Erasmus University Medical Center. The median survival increased by approximately 200% for patients treated with Ampligen compared to historical controls. AIM aims to seek FDA Fast Track designation and orphan drug status for Ampligen as a treatment for late-stage pancreatic cancer. The company will collaborate with Amarex Clinical Research to initiate a Phase 2/3 clinical trial in the Netherlands and the U.S., seeking to extend exclusivity rights for Ampligen.

AIM ImmunoTech Inc. (NYSE American:AIM) announced the start of recruitment for a Phase 1/2a clinical trial at Roswell Park Comprehensive Cancer Center. The trial investigates the use of rintatolimod (Ampligen) combined with interferon alpha-2b for cancer patients with mild to moderate COVID-19. This study aims to leverage 20 years of cancer immunotherapy research to engage the innate immune system against SARS-CoV-2 and other RNA viruses. The trial is funded with support from the National Cancer Institute and AIM.